KantorED, RehmCD, HaasJS, et al.Trends in prescription drug use among adults in the United States from 1999-2012. JAMA2015;314(17):1818-1831; doi: 10.1001/jama.2015.13766.
2.
AyalaIN, Soto JacomeC, Toro-TobonD. Appropriateness of levothyroxine prescription: A multicenter retrospective study. Supplemental table1. 2023. Figshare; doi: 10.6084/m9.figshare.24033891.
3.
van der SpoelE, van VlietNA, PoortvlietRKE, et al.Incidence and determinants of spontaneous normalization of subclinical hypothyroidism in older adults. J Clin Endocrinol Metab2024;109(3):e1167-e1174; doi: 10.1210/clinem/dgad623.
4.
StottDJ, RodondiN, KearneyPM, et al.Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med2017;376(26):2534-2544; doi: 10.1056/NEJMoa1603825.
5.
AdamsR, OhES, YasarS, et al.Endogenous and exogenous thyrotoxicosis and risk of incident cognitive disorders in older adults. JAMA Intern Med2023;183(12):1324-1331; doi: 10.1001/jamainternmed.2023.5619.
6.
RavensbergJ, GusseklooJ, Le CessieS, et al.Discontinuation of levothyroxine in adults aged 60 years or older. JAMA2026:e262864; doi: 10.1001/jama.2026.2864.
7.
PearceSH, BrabantG, DuntasLH, et al.2013 ETA guideline: Management of subclinical hypothyroidism. Eur Thyroid J2013;2(4):215-228; doi: 10.1159/000356507.
8.
MarakaS, PapaleontiouM. Approach to the patient considering thyroid hormone deprescribing. J Clin Endocrinol Metab2026;111(4):1169-1174; doi: 10.1210/clinem/dgaf697.
9.
HidalgoJ, VallejoBA, Soto JacomeC, et al.Real practice assessment of persistent symptoms after initiation of levothyroxine. Endocr Pract2024;30(2):95-100; doi: 10.1016/j.eprac.2023.10.132.
10.
JungKY, KimH, ChoiHS, et al.Clinical factors predicting the successful discontinuation of hormone replacement therapy in patients diagnosed with primary hypothyroidism. PLoS One2020;15(5):e0233596; doi: 10.1371/journal.pone.0233596.
